在纤维肌痛和刺激性肠综合征中严重的多种药物不耐受症候群
Alicia A Alvarez1, Jayme M Palka2, David A Khan3
1First Physicians Group, Sarasota Memorial Hospital, Sarasota, Fla.
The journal of allergy and clinical immunology. In practice
|January 26, 2024
概括
患有纤维肌痛和刺激性肠综合征 (IBS) 的患者患重症多重药物不耐症综合征 (MDIS) 的患病率更高. 这种情况与多药学有关,需要进一步研究有效的管理策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 患者安全 患者安全
背景情况:
- 多种药物不耐症综合征 (MDIS) 涉及非免疫学药物不良反应.
- 严重的MDIS是由10多种药物不耐受性标签定义的.
- 肌肉纤维肌痛症和刺激性肠综合征 (IBS) 的特征与MDIS相同,使治疗复杂化.
研究的目的:
- 为了确定纤维肌痛和IBS患者中严重MDIS的患病率.
- 在这些患者群体中确定与严重的MDIS相关的风险因素.
主要方法:
- 从2019年8月到2020年7月,对纤维肌痛或IBS患者的回顾性图表审查.
- 与随机选择,匹配的对照进行比较.
- 分析药物不耐受性数据和患者特征,使用后勤回归和千平方测试.
主要成果:
- 纤维肌痛和IBS患者患重度MDIS的可能性分别是对照组的12倍和3倍.
- 在这两组患者中,严重的MDIS与多药学相关.
- 片不耐受是最常见的;IBS患者报告了更多的胃肠道症状,而纤维肌痛患者没有报告更多的疼痛或行为问题.
结论:
- 在患有纤维肌痛和IBS的患者中,严重的MDIS的发病率较高.
- 进一步的研究是必要的,以了解MDIS的发病率,并优化其管理在这些人群.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Irritable Bowel Syndrome I: Introduction
276
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
276
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Chronic Bowel Disorders: Introduction
450
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
450
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
161
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
161
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166


